Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial

Jean Louis Selam, Luigi F. Meneghini

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: The aim of this study was to compare a simplified patient-driven algorithm (303 Algorithm) to physician-driven adjustments in a subset of 193 patients with type 2 diabetes from the PREDICTIVE 303 study who were using basal-bolus insulin therapy. Methods: PREDICTIVE 303 was a 26-week, randomized, phase 4 study, in which subjects were either instructed to adjust their insulin detemir dose every 3 days by ±3 units if mean fasting plasma glucose (FPG) values were above 110 mg/dL or below 80 mg/dL (303 Algorithm), or had physicians adjust the insulin detemir dose according to usual practice (Standard-of-care). Results: Patients in both groups achieved similar reductions in glycated hemoglobin (-0.2% and -0.3% for 303 Algorithm and Standard-of care groups, respectively; between groups P=0.60). 303 Algorithm group patients achieved a greater reduction in FPG (-21.3 mg/dL vs. 0.2 mg/dL; between groups P=0.03). Both 303 Algorithm and Standard-of care groups experienced a similar rate of overall hypoglycemia, and similar weight reduction (-1.7 kg and -0.4 kg, respectively; between groups P=0.07). Over 82% of patients in both groups used insulin detemir once daily. Conclusions: Adjustments of a once-daily detemir dose by patients using the 303 Algorithm in a basalbolus setting is equally effective in improving glycemic control in patients with type 2 diabetes compared with physician-directed basal dose adjustments.

Original languageEnglish
Pages (from-to)194-207
Number of pages14
JournalAdvances in Therapy
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

Social Adjustment
Standard of Care
Physicians
Type 2 Diabetes Mellitus
Therapeutics
Fasting
Glucose
Glycosylated Hemoglobin A
Insulin Detemir
Hypoglycemia
Weight Loss
Insulin

Keywords

  • Basal-bolus
  • Insulin detemir
  • Insulin titration
  • Long-acting insulin analog
  • PREDICTIVE 303
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. / Selam, Jean Louis; Meneghini, Luigi F.

In: Advances in Therapy, Vol. 26, No. 2, 01.02.2009, p. 194-207.

Research output: Contribution to journalArticle

Selam, Jean Louis ; Meneghini, Luigi F. / Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. In: Advances in Therapy. 2009 ; Vol. 26, No. 2. pp. 194-207.
@article{480d1cda40ef49e5aada2d1442c0ab19,
title = "Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial",
abstract = "Introduction: The aim of this study was to compare a simplified patient-driven algorithm (303 Algorithm) to physician-driven adjustments in a subset of 193 patients with type 2 diabetes from the PREDICTIVE 303 study who were using basal-bolus insulin therapy. Methods: PREDICTIVE 303 was a 26-week, randomized, phase 4 study, in which subjects were either instructed to adjust their insulin detemir dose every 3 days by ±3 units if mean fasting plasma glucose (FPG) values were above 110 mg/dL or below 80 mg/dL (303 Algorithm), or had physicians adjust the insulin detemir dose according to usual practice (Standard-of-care). Results: Patients in both groups achieved similar reductions in glycated hemoglobin (-0.2{\%} and -0.3{\%} for 303 Algorithm and Standard-of care groups, respectively; between groups P=0.60). 303 Algorithm group patients achieved a greater reduction in FPG (-21.3 mg/dL vs. 0.2 mg/dL; between groups P=0.03). Both 303 Algorithm and Standard-of care groups experienced a similar rate of overall hypoglycemia, and similar weight reduction (-1.7 kg and -0.4 kg, respectively; between groups P=0.07). Over 82{\%} of patients in both groups used insulin detemir once daily. Conclusions: Adjustments of a once-daily detemir dose by patients using the 303 Algorithm in a basalbolus setting is equally effective in improving glycemic control in patients with type 2 diabetes compared with physician-directed basal dose adjustments.",
keywords = "Basal-bolus, Insulin detemir, Insulin titration, Long-acting insulin analog, PREDICTIVE 303, Type 2 diabetes",
author = "Selam, {Jean Louis} and Meneghini, {Luigi F.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1007/s12325-009-0007-8",
language = "English",
volume = "26",
pages = "194--207",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "2",

}

TY - JOUR

T1 - Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial

AU - Selam, Jean Louis

AU - Meneghini, Luigi F.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Introduction: The aim of this study was to compare a simplified patient-driven algorithm (303 Algorithm) to physician-driven adjustments in a subset of 193 patients with type 2 diabetes from the PREDICTIVE 303 study who were using basal-bolus insulin therapy. Methods: PREDICTIVE 303 was a 26-week, randomized, phase 4 study, in which subjects were either instructed to adjust their insulin detemir dose every 3 days by ±3 units if mean fasting plasma glucose (FPG) values were above 110 mg/dL or below 80 mg/dL (303 Algorithm), or had physicians adjust the insulin detemir dose according to usual practice (Standard-of-care). Results: Patients in both groups achieved similar reductions in glycated hemoglobin (-0.2% and -0.3% for 303 Algorithm and Standard-of care groups, respectively; between groups P=0.60). 303 Algorithm group patients achieved a greater reduction in FPG (-21.3 mg/dL vs. 0.2 mg/dL; between groups P=0.03). Both 303 Algorithm and Standard-of care groups experienced a similar rate of overall hypoglycemia, and similar weight reduction (-1.7 kg and -0.4 kg, respectively; between groups P=0.07). Over 82% of patients in both groups used insulin detemir once daily. Conclusions: Adjustments of a once-daily detemir dose by patients using the 303 Algorithm in a basalbolus setting is equally effective in improving glycemic control in patients with type 2 diabetes compared with physician-directed basal dose adjustments.

AB - Introduction: The aim of this study was to compare a simplified patient-driven algorithm (303 Algorithm) to physician-driven adjustments in a subset of 193 patients with type 2 diabetes from the PREDICTIVE 303 study who were using basal-bolus insulin therapy. Methods: PREDICTIVE 303 was a 26-week, randomized, phase 4 study, in which subjects were either instructed to adjust their insulin detemir dose every 3 days by ±3 units if mean fasting plasma glucose (FPG) values were above 110 mg/dL or below 80 mg/dL (303 Algorithm), or had physicians adjust the insulin detemir dose according to usual practice (Standard-of-care). Results: Patients in both groups achieved similar reductions in glycated hemoglobin (-0.2% and -0.3% for 303 Algorithm and Standard-of care groups, respectively; between groups P=0.60). 303 Algorithm group patients achieved a greater reduction in FPG (-21.3 mg/dL vs. 0.2 mg/dL; between groups P=0.03). Both 303 Algorithm and Standard-of care groups experienced a similar rate of overall hypoglycemia, and similar weight reduction (-1.7 kg and -0.4 kg, respectively; between groups P=0.07). Over 82% of patients in both groups used insulin detemir once daily. Conclusions: Adjustments of a once-daily detemir dose by patients using the 303 Algorithm in a basalbolus setting is equally effective in improving glycemic control in patients with type 2 diabetes compared with physician-directed basal dose adjustments.

KW - Basal-bolus

KW - Insulin detemir

KW - Insulin titration

KW - Long-acting insulin analog

KW - PREDICTIVE 303

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=73449124778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449124778&partnerID=8YFLogxK

U2 - 10.1007/s12325-009-0007-8

DO - 10.1007/s12325-009-0007-8

M3 - Article

VL - 26

SP - 194

EP - 207

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 2

ER -